Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Compassionate Use Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Next Previous
X
Search
Trial Profile

A Multicenter Compassionate Use Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Aug 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Expanded access; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 07 Sep 2016 Results (N=485) assessing safety and efficacy published in the Gut (2016).
    • 17 Apr 2016 Results of subanalysis of HCV-infected patients (n=147) with decompensated cirrhosis treated with a combination of daclatasvir + sofosbuvir +/- ribavirin were presented at The International Liver Congress™ 2016.
    • 26 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top